Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations (Nature Cancer, (2023), 4, 9, (1345-1361), 10.1038/s43018-023-00630-y)

Isao Miyazaki; Igor Odintsov; Keiji Ishida; Allan J.W. Lui; Masanori Kato; Tatsuya Suzuki; Tom Zhang; Kentaro Wakayama; Renate I. Kurth; Ryan Cheng; Hidenori Fujita; Lukas Delasos; Morana Vojnic; Inna Khodos; Yukari Yamada; Kota Ishizawa; Marissa S. Mattar; Kaoru Funabashi; Qing Chang; Shuichi Ohkubo; Wakako Yano; Ryuichiro Terada; Claudio Giuliano; Yue Christine Lu; Annalisa Bonifacio; Siddharth Kunte; Monika A. Davare; Emily H. Cheng; Elisa de Stanchina; Emanuela Lovati; Yoshikazu Iwasawa; Marc Ladanyi; Romel Somwar

doi:10.1038/s43018-023-00663-3

Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations (Nature Cancer, (2023), 4, 9, (1345-1361), 10.1038/s43018-023-00630-y)

Isao Miyazaki, Igor Odintsov, Keiji Ishida, Allan J.W. Lui, Masanori Kato, Tatsuya Suzuki, Tom Zhang, Kentaro Wakayama, Renate I. Kurth, Ryan Cheng, Hidenori Fujita, Lukas Delasos, Morana Vojnic, Inna Khodos, Yukari Yamada, Kota Ishizawa, Marissa S. Mattar, Kaoru Funabashi, Qing Chang, Shuichi OhkuboWakako Yano, Ryuichiro Terada, Claudio Giuliano, Yue Christine Lu, Annalisa Bonifacio, Siddharth Kunte, Monika A. Davare, Emily H. Cheng, Elisa de Stanchina, Emanuela Lovati, Yoshikazu Iwasawa, Marc Ladanyi, Romel Somwar

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Correction to: Nature Cancer, published online 21 September 2023. In the version of the article initially published, the affiliation of Ryan Cheng was incorrect and has now been updated to the Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, in the HTML and PDF versions of the article.

Original language	English (US)
Pages (from-to)	1526
Number of pages	1
Journal	Nature Cancer
Volume	4
Issue number	10
DOIs	https://doi.org/10.1038/s43018-023-00663-3
State	Published - Oct 2023

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1038/s43018-023-00663-3

Fingerprint

Dive into the research topics of 'Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations (Nature Cancer, (2023), 4, 9, (1345-1361), 10.1038/s43018-023-00630-y)'. Together they form a unique fingerprint.

Cite this

Miyazaki, I., Odintsov, I., Ishida, K., Lui, A. J. W., Kato, M., Suzuki, T., Zhang, T., Wakayama, K., Kurth, R. I., Cheng, R., Fujita, H., Delasos, L., Vojnic, M., Khodos, I., Yamada, Y., Ishizawa, K., Mattar, M. S., Funabashi, K., Chang, Q., ... Somwar, R. (2023). Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations (Nature Cancer, (2023), 4, 9, (1345-1361), 10.1038/s43018-023-00630-y). Nature Cancer, 4(10), 1526. https://doi.org/10.1038/s43018-023-00663-3

Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations (Nature Cancer, (2023), 4, 9, (1345-1361), 10.1038/s43018-023-00630-y). / Miyazaki, Isao; Odintsov, Igor; Ishida, Keiji et al.
In: Nature Cancer, Vol. 4, No. 10, 10.2023, p. 1526.

Research output: Contribution to journal › Comment/debate › peer-review

Miyazaki, I, Odintsov, I, Ishida, K, Lui, AJW, Kato, M, Suzuki, T, Zhang, T, Wakayama, K, Kurth, RI, Cheng, R, Fujita, H, Delasos, L, Vojnic, M, Khodos, I, Yamada, Y, Ishizawa, K, Mattar, MS, Funabashi, K, Chang, Q, Ohkubo, S, Yano, W, Terada, R, Giuliano, C, Lu, YC, Bonifacio, A, Kunte, S, Davare, MA, Cheng, EH, de Stanchina, E, Lovati, E, Iwasawa, Y, Ladanyi, M & Somwar, R 2023, 'Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations (Nature Cancer, (2023), 4, 9, (1345-1361), 10.1038/s43018-023-00630-y)', Nature Cancer, vol. 4, no. 10, pp. 1526. https://doi.org/10.1038/s43018-023-00663-3

Miyazaki I, Odintsov I, Ishida K, Lui AJW, Kato M, Suzuki T et al. Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations (Nature Cancer, (2023), 4, 9, (1345-1361), 10.1038/s43018-023-00630-y). Nature Cancer. 2023 Oct;4(10):1526. doi: 10.1038/s43018-023-00663-3

@article{10c6643c25244ac88d6c170f829aa530,

title = "Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations (Nature Cancer, (2023), 4, 9, (1345-1361), 10.1038/s43018-023-00630-y)",

abstract = "Correction to: Nature Cancer, published online 21 September 2023. In the version of the article initially published, the affiliation of Ryan Cheng was incorrect and has now been updated to the Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, in the HTML and PDF versions of the article.",

author = "Isao Miyazaki and Igor Odintsov and Keiji Ishida and Lui, {Allan J.W.} and Masanori Kato and Tatsuya Suzuki and Tom Zhang and Kentaro Wakayama and Kurth, {Renate I.} and Ryan Cheng and Hidenori Fujita and Lukas Delasos and Morana Vojnic and Inna Khodos and Yukari Yamada and Kota Ishizawa and Mattar, {Marissa S.} and Kaoru Funabashi and Qing Chang and Shuichi Ohkubo and Wakako Yano and Ryuichiro Terada and Claudio Giuliano and Lu, {Yue Christine} and Annalisa Bonifacio and Siddharth Kunte and Davare, {Monika A.} and Cheng, {Emily H.} and {de Stanchina}, Elisa and Emanuela Lovati and Yoshikazu Iwasawa and Marc Ladanyi and Romel Somwar",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2023",

month = oct,

doi = "10.1038/s43018-023-00663-3",

language = "English (US)",

volume = "4",

pages = "1526",

journal = "Nature Cancer",

issn = "2662-1347",

publisher = "Nature Research",

number = "10",

}

TY - JOUR

T1 - Author Correction

T2 - Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations (Nature Cancer, (2023), 4, 9, (1345-1361), 10.1038/s43018-023-00630-y)

AU - Miyazaki, Isao

AU - Odintsov, Igor

AU - Ishida, Keiji

AU - Lui, Allan J.W.

AU - Kato, Masanori

AU - Suzuki, Tatsuya

AU - Zhang, Tom

AU - Wakayama, Kentaro

AU - Kurth, Renate I.

AU - Cheng, Ryan

AU - Fujita, Hidenori

AU - Delasos, Lukas

AU - Vojnic, Morana

AU - Khodos, Inna

AU - Yamada, Yukari

AU - Ishizawa, Kota

AU - Mattar, Marissa S.

AU - Funabashi, Kaoru

AU - Chang, Qing

AU - Ohkubo, Shuichi

AU - Yano, Wakako

AU - Terada, Ryuichiro

AU - Giuliano, Claudio

AU - Lu, Yue Christine

AU - Bonifacio, Annalisa

AU - Kunte, Siddharth

AU - Davare, Monika A.

AU - Cheng, Emily H.

AU - de Stanchina, Elisa

AU - Lovati, Emanuela

AU - Iwasawa, Yoshikazu

AU - Ladanyi, Marc

AU - Somwar, Romel

PY - 2023/10

Y1 - 2023/10

N2 - Correction to: Nature Cancer, published online 21 September 2023. In the version of the article initially published, the affiliation of Ryan Cheng was incorrect and has now been updated to the Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, in the HTML and PDF versions of the article.

AB - Correction to: Nature Cancer, published online 21 September 2023. In the version of the article initially published, the affiliation of Ryan Cheng was incorrect and has now been updated to the Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, in the HTML and PDF versions of the article.

UR - http://www.scopus.com/inward/record.url?scp=85173936644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85173936644&partnerID=8YFLogxK

U2 - 10.1038/s43018-023-00663-3

DO - 10.1038/s43018-023-00663-3

M3 - Comment/debate

C2 - 37814012

AN - SCOPUS:85173936644

SN - 2662-1347

VL - 4

SP - 1526

JO - Nature Cancer

JF - Nature Cancer

IS - 10

ER -

Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations (Nature Cancer, (2023), 4, 9, (1345-1361), 10.1038/s43018-023-00630-y)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this